Welcome to our dedicated page for Sirona Biochem news (Ticker: SRBCF), a resource for investors and traders seeking the latest updates and insights on Sirona Biochem stock.
The news feed for Sirona Biochem Corp. (SRBCF) brings together company-issued updates that describe its activities as a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona Biochem focuses on stabilizing carbohydrate molecules to improve efficacy and safety and reports that it licenses its compounds to cosmetics, pharmaceutical, and other leading companies in exchange for licensing fees, milestone payments or milestone fees, and royalties.
Investors and observers following Sirona Biochem’s news can review announcements about its anti-aging skincare ingredient GlycoProteMim™ (also known as TFC-1326), trademark developments, and the creation of its commercialization subsidiary Sirona Laboratories™. The company has issued updates on formulation work for GlycoProteMim with Global Beauty Consulting, advisory engagements with Stonegate Healthcare Partners, and plans for product launches through Sirona Laboratories in Europe and North America.
Sirona Biochem’s releases also cover licensing and partnership activities, including its exclusive global licensing agreement with Allergan Aesthetics for TFC-1067 and later communication that Allergan Aesthetics would not proceed with the license agreement regarding commercialization of that compound. Corporate updates address financing initiatives such as private placements and convertible debenture offerings, as well as efforts to secure strategic investment and non-dilutive funding.
More recent news highlights significant financial and operational challenges, including the failure of an expected investment from Promura GmbH to close, the decision to allow for the orderly liquidation of its wholly owned laboratory subsidiary TFChem under French bankruptcy regulations, the cessation of laboratory operations, and the issuance of a cease trade order in March 2025. Readers can use this news stream to understand how Sirona Biochem describes its evolving strategy, pipeline priorities in cosmetic and therapeutic skincare, and the risks and uncertainties it has identified around financing and commercialization.
Sirona Biochem (TSX-V: SBM) announced significant operational and financial challenges. The company's recent convertible debenture financing attempt failed to secure sufficient investor participation, following a similar unsuccessful attempt last year. The previously announced investment agreement with Promura GmbH has fallen through, with committed funds never materializing.
Due to financial constraints, Sirona has initiated the liquidation of its subsidiary TFChem, resulting in the permanent closure of laboratory operations. The company is under a cease trade order since March 7, 2025. Additionally, Allergan Aesthetics has withdrawn from the TFC-1067 license agreement originally announced in June 2022. Management is currently evaluating options for potential future development while operating without salaries.
Sirona Biochem Corp. has partnered with Stonegate Healthcare Partners to evaluate its anti-aging ingredient GlycoProteMimTM. Stonegate is a Dallas-based corporate advisory firm providing research-driven business development and investor outreach services. The partnership aims to assess and demonstrate the market potential of GlycoProteMimTM in the global anti-aging skincare industry.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sirona Biochem Corp (OTC: SRBCF) announced strategic corporate changes following an exclusive global licensing agreement with Allergan Aesthetics. The Board is reviewing all company aspects, including management and project pipeline, aiming for sustainable growth. Additionally, organizational enhancements will occur in Vancouver and Rouen, France, to expedite project development. Sirona plans to strengthen its market presence, enhance investor relations, and pursue up listing opportunities. Continuous updates on these initiatives will be provided throughout 2022.